Treatment of Recurrent Oral Thrush Unresponsive to Topical Agents

First-Line Treatment

The Infectious Diseases Society of America recommends oral fluconazole 100-200 mg daily for 7-14 days as the first-line treatment for recurrent oral thrush unresponsive to nystatin or amphotericin lozenges, with a strong recommendation and moderate-quality evidence 1, 2
For severe cases, the dose of fluconazole may be increased to 200-400 mg daily, as recommended by the Infectious Diseases Society of America 1, 3

The Centers for Disease Control and Prevention recommends itraconazole oral solution 200 mg daily for up to 28 days as an alternative treatment for fluconazole-refractory cases, with a strong recommendation and moderate-quality evidence 1, 5
Posaconazole suspension 400 mg twice daily for 3 days, then 400 mg daily for up to 28 days is also recommended by the Centers for Disease Control and Prevention as an alternative treatment 1, 4

The Infectious Diseases Society of America recommends intravenous echinocandins, such as caspofungin, micafungin, or anidulafungin, for severe refractory cases that fail to respond to oral azole therapy 1, 3
Intravenous amphotericin B deoxycholate 0.3 mg/kg daily is also recommended by the Infectious Diseases Society of America for severe refractory cases 1

The Centers for Disease Control and Prevention recommends suppressive therapy with fluconazole 100 mg three times weekly for patients with frequent recurrences of oral thrush 1, 6
Identifying and addressing underlying causes, such as immunosuppression or denture-related candidiasis, is essential for effective management, as recommended by the Infectious Diseases Society of America 1, 4

The Infectious Diseases Society of America recommends considering Candida species identification and antifungal susceptibility testing in refractory cases 6
Non-albicans Candida species, particularly C. glabrata, may be resistant to azoles and respond better to echinocandins or amphotericin B, as noted by the Infectious Diseases Society of America 1

Systemic antifungal therapy is always required for refractory cases, as recommended by the Infectious Diseases Society of America 1, 3
A diagnostic trial of antifungal therapy is appropriate before performing an endoscopic examination, as recommended by the Infectious Diseases Society of America 1
Treatment duration should typically be 7-14 days for oropharyngeal candidiasis, but may need to be extended to 14-21 days for more severe or refractory cases, as recommended by the Infectious Diseases Society of America 1, 3
Patients with immunosuppression may require longer courses of therapy or maintenance treatment, as recommended by the Centers for Disease Control and Prevention 7, 4